Asthma pill tested to fight ovarian Cancer's return
NCT ID NCT04339140
Summary
This study tested whether zafirlukast, a drug approved for asthma, could help control early signs of ovarian cancer returning. It involved a small group of patients whose only sign of relapse was a rising blood marker (CA-125), with no visible tumors on scans. The main goal was to see if the drug could significantly lower this marker, which might indicate it's slowing the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.